- Pharma
- 1 min read
‘Vax halves risk of long Covid’
The study also provides more evidence that the two-shot Pfizer- BioNTech, Moderna and AstraZeneca vaccines offer powerful protection against symptomatic and severe disease.
The study, which was published in Lancet Infectious Diseases journal on Wednesday, also provides more evidence that the two-shot Pfizer- BioNTech, Moderna and AstraZeneca vaccines offer powerful protection against symptomatic and severe disease. “This is the first study showing that long Covid is reduced by double vaccination,” said lead author Claire Steves of King’s College London.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions